A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study (WJOG5610L).
Takashi Seto(National Hospital Organization Kyushu Cancer Center), Yoichi Nakanishi(RIKEN Center for Integrative Medical Sciences), Akira Ono(Shizuoka Cancer Center), Nobuyuki Yamamoto(Wakayama Medical University), Kazumi Nishino(Osaka Medical Center for Cancer and Cardiovascular Diseases), Hiroshige Yoshioka(Harbin Medical University), Hidetoshi Hayashi(Kindai University), Koichi Azuma(Kyushu University Hospital), Atsushi Horiike(The Cancer Institute Hospital), Shigeki Mitsuoka(Osaka City University), Shinji Atagi(National Institute of Technology, Nara College), Isamu Okamoto(Kyushu University Hospital), Haruko Daga(Osaka City General Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Daichi Fujimoto(Hyogo University), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Hideo Saka(Nagoya Medical Center), Yasuo Iwamoto(Hiroshima City Asa Citizens Hospital), Takashi Sone(Kanazawa University Hospital), Takeharu Yamanaka(National Cancer Center Hospital East)
Cited by 3
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k